HETEROCYCLIC COMPOUNDS FOR TYROSINE KINASE 2 ACTIVITY MEDIATION Russian patent published in 2024 - IPC C07D487/04 C07D403/14 C07D403/04 C07D405/14 A61K31/506 A61K31/5377 A61P1/04 A61P3/10 A61P11/00 A61P17/06 A61P25/28 A61P27/02 A61P35/00 A61P37/00 

FIELD: chemistry; pharmaceutics.

SUBSTANCE: present invention relates to heterocyclic compounds or pharmaceutically acceptable salts thereof, suitable for controlling or inhibiting Janus kinase (JAK) activity, in particular tyrosine kinase 2 (TYK2), specifically to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a stable isotope, a stereoisomer, in which R¹ is pyrazolyl, where one pyrazolyl hydrogen is optionally substituted -COOR^b, -C(O)R^b, -C(O)NR^bR^c, C_1–6alkyl, CD₃ or piperidinyl; R² is H; R³ is H, halogen, cyano, C_1-6 alkyl, or OC_1–6alkyl; R⁴ and R⁵ are independently selected from H, or C_1-6 alkyl; R⁶ and R⁷ are independently selected from H, or R⁶ and R⁷ are combined in the form of oxo; L is a bond, C_1-6 alkylene, -C(O)-, -C(O)O-, -C(O)N(R^a)- or -S(O)₂-; A is H, C_1-6alkyl, C_3-6 cycloalkyl, 4-membered heterocyclyl, in which one ring atom is N or O, or 5–6-membered heteroaryl, in which from 1 to 3 ring atoms are N or O heteroatoms, where one or more hydrogen atoms of alkyl, cycloalkyl and heteroaryl are optionally substituted with halogen, cyano or -OR^d; R^a represents H; R^b and R^c are independently selected from H or C_1-6alkyl, and R^d is independently selected from H, C_1–6 alkyl or morpholinyl. Invention also relates to specific compounds, as well as to a pharmaceutical composition based on said compounds.

EFFECT: obtaining alternative compounds for treating TYK2-mediated diseases.

11 cl, 101 ex